<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581786</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-015-III-NPC</org_study_id>
    <nct_id>NCT03581786</nct_id>
  </id_info>
  <brief_title>Phase III Study of Comparing TORIPALIMAB INJECTION Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasophapyngeal Cancer</brief_title>
  <official_title>A PHASE III, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER, DOUBLE BLIND STUDY COMPARING TORIPALIMAB INJECTION（JS001） COMBINED WITH CHEMOTHERAPY VERSUS PLACEBO COMBINED WITH CHEMOTHERAPY FOR RECURRENT OR METASTATIC NASOPHARYNGEAL CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to
      determine the efficacy and safety of TORIPALIMAB INJECTIO（JS001） in combination with
      gemcitabine/cisplatin compared with placebo in combination with gemcitabine/cisplatin as
      first-line treatment in patients with histological/cytological confirmation of recurrent or
      metastatic NPC. The primary endpoint is PFS in all patients. Approximately 280 patients who
      fulfill all of the inclusion criteria and none of the exclusion criteria will be randomized
      in a 1:1 ratio to one of the two treatment arms. patients will be randomly assigned to the
      combination of JS001 (Arm A) or placebo (Arm B) with gemcitabine and cisplatin given every 3
      weeks (Q3W) in 3-week cycles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">August 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001 )plus chemotherapy compared with placebo plus chemotherapy，as measured by investigator-assessed progression free survival (PFS) according to RECIST v1.1 in all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001 )plus chemotherapy compared with placebo plus chemotherapy, as measured by overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>From date of response until progressive disease. Up to 2 approximately years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001 )plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed duration of response (DoR) according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed disease control rate (DCR) according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iDMC-assessed PFS</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by an independent monitoring committee (iDMC)-assessed PFS according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS rate</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate the PFS rate at 1 and 2 years in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate</measure>
    <time_frame>From date of randomization until death, loss to follow-up, or study termination by the Sponsor whichever occurs first.Up to 3.5 approximately years</time_frame>
    <description>To evaluate the OS rate at 1 and 2 years in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes collected via the EORTC QLQ-C30</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>health related quality of life (HRQoL) in patients treated with JS001 plus chemotherapy compared with placebo plus chemotherapy using the EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes collected via the EORTC QLQ-H&amp;N35</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>health related quality of life (HRQoL) in patients treated with JS001 plus chemotherapy compared with placebo plus chemotherapy using the EORTC QLQ-H&amp;N35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health related quality of life using ECOG performance status</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>health related quality of life (HRQoL) in patients treated with JS001 plus chemotherapy compared with placebo plus chemotherapy using ECOG performance status assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>From date of consent informed until 60 days after the last investigational product administration. Up to 2 approximately years</time_frame>
    <description>Incidence and severity of adverse events as assessed by CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events(SAE) as assessed by CTCAE version 5.0</measure>
    <time_frame>From date of consent informed until 60 days after the last investigational product administration. Up to 2 approximately years</time_frame>
    <description>Incidence of serious adverse events(SAE) as assessed by CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAs</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate the incidence and titers of ADAs against JS001 and to explore the potential relationship of the immunogenicity response with pharmacodynamics, safety and efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assessed per irRECIST</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate PFS of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR assessed per irRECIST</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate ORR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR assessed per irRECIST</measure>
    <time_frame>From date of response until progressive disease. Up to 2 approximately years</time_frame>
    <description>To evaluate DoR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR assessed per irRECIST</measure>
    <time_frame>From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years</time_frame>
    <description>To evaluate DCR of JS001 plus chemotherapy compared with placebo plus chemotherapy according to irRECIST.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Recurrent or Metastatic NPC</condition>
  <arm_group>
    <arm_group_label>placebo combine with chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TORIPALIMAB INJECTION(JS001 )combine with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy</intervention_name>
    <description>TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy</description>
    <arm_group_label>TORIPALIMAB INJECTION(JS001 )combine with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>placebo combine with chemotherapy</description>
    <arm_group_label>placebo combine with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 18 years and ≤75 years.

          -  2. Histological/cytological confirmation of NPC.

          -  3. Primarily metastatic (stage IVB as defined by the International Union against
             Cancer and American Joint Committee on Cancer staging system for NPC, eighth edition)
             or recurrent NPC that is not amenable for local regional treatment or curative
             treatment.

          -  4. At least 1 measurable lesion according to RECIST version 1.1.

          -  5. Life expectancy ≥ 3 months

        Exclusion Criteria:

          -  1. History of severe hypersensitivity reactions to other mAbs or any ingredient of
             JS001.

          -  2. Prior therapy targeting PD-1 receptor, or its ligand PD-L1, or cytotoxic T
             lymphocyte associated protein 4 (CTLA4) receptor.

          -  3. Major surgical procedure other than for diagnosis of NPC within 28 days prior to
             randomization or anticipation of need for a major surgical procedure during the study

          -  4. History of hypersensitivity to gemcitabine or cisplatin or to any of the
             excipients.

          -  5. Female patients who are at pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wang Xiaojun</last_name>
    <phone>+86 18224042444</phone>
    <email>xiaojun_wang@topalliancebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute &amp; Hospital, Chinese Academy of Medical Scie</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohui He, Dr</last_name>
      <email>xiaohuih2008@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaohui He, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin, Ms</last_name>
      <email>13950482366@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoyan Lin, Ms</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianji Pan, Dr</last_name>
      <email>panjianji@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianji Pan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Prof</last_name>
      <email>ruihxu@163.com</email>
    </contact>
    <investigator>
      <last_name>Ruihua Xu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dongping Chen, Dr</last_name>
      <email>chen_dpgz@163.com</email>
    </contact>
    <investigator>
      <last_name>Dongping Chen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wangjun Liao, Prof</last_name>
      <email>nfyyliaowj@163.com</email>
    </contact>
    <investigator>
      <last_name>Wangjun Liao, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruilian Xu, Prof</last_name>
      <email>xuruilian@126.com</email>
    </contact>
    <investigator>
      <last_name>Ruilian Xu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liuzhou Worker's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Lu, Dr</last_name>
      <email>1786734840@qq.com</email>
    </contact>
    <investigator>
      <last_name>Ying Lu, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shenhong Qu, Prof</last_name>
      <email>qshdoctor@163.com</email>
    </contact>
    <investigator>
      <last_name>Shenhong Qu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangzhou</state>
        <zip>515031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi JIANG, Dr</last_name>
      <email>jiangzy_123@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yi JIANG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangzhou</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiyu Wen, Prof</last_name>
      <email>15812388788@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiyu Wen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital_Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Jin, Prof</last_name>
      <email>jinf8865@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Feng Jin, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital (Hainan Province People's Hospital)</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanju Chen, Dr</last_name>
      <email>cyj-0001@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanju Chen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanghua Jing, Dr</last_name>
      <email>jingsh2009@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shanghua Jing, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, Prof</last_name>
      <email>13313612989@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology- Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, Dr</last_name>
      <email>octtongji@163.com</email>
    </contact>
    <investigator>
      <last_name>Xianglin Yuan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology- Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kunyu Yang, Dr</last_name>
      <email>yangkunyu@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Kunyu Yang, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunhong Hu, Prof</last_name>
      <email>huchunh5829@126.com</email>
    </contact>
    <investigator>
      <last_name>Chunhong Hu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingrui Shi, Prof</last_name>
      <email>shiyingrui@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yingrui Shi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingao Li, Dr</last_name>
      <email>lijingao@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jingao Li, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chaosu Hu, Dr</last_name>
      <email>hucsu62@163.com</email>
    </contact>
    <investigator>
      <last_name>Chaosu Hu, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai first people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qi Li, Prof</last_name>
      <email>leeqi2001@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qi Li, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Li, Prof</last_name>
      <email>leepingmd68@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Ping Li, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, Dr</last_name>
      <email>cxzfyun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaozhong Chen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wan-Teck Darren Lim, Dr</last_name>
      <email>dmolwt@nccs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Wan-Teck Darren Lim, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raffles Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tan Min Chin, Dr</last_name>
      <email>chin_tanmin@rafflesmedical.com</email>
    </contact>
    <investigator>
      <last_name>Tan Min Chin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Samol, Dr</last_name>
      <email>jens_samol@ttsh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Jens Samol, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center - Liouying Branch</name>
      <address>
        <city>Liuying</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chien-Liang Lin, Dr</last_name>
      <email>kevin640209@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chien-Liang Lin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ching-Yun Hsieh, Dr</last_name>
      <email>tsienkoala@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Ching-Yun Hsieh, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TaiChung Veterans General Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Ching Lin, Dr</last_name>
      <email>jclin@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Jin-Ching Lin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chia-Jui Yen, Dr</last_name>
      <email>yencj0731@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chia-Jui Yen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruey-Long Hong, Dr</last_name>
      <email>rlhong@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ruey-Long Hong, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muh-Hwa Yang, Dr</last_name>
      <email>mhyang2@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Muh-Hwa Yang, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hung-Ming Wang, Dr</last_name>
      <email>whm526@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Hung-Ming Wang, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

